STK11 and lung adenocarcinoma: A Phase II clinical trial, FAME, is currently underway to evaluate the effectiveness of metformin alone or in combination with a fasting-mimicking diet to improve standard chemotherapy outcomes for patients with LKB1-mutant lung adenocarcinoma (Vernieri et al., 2019).